Concentrix stock price slips as CNXC bucks Wall Street rally on jobs-day

Concentrix stock price slips as CNXC bucks Wall Street rally on jobs-day

February 11, 2026

New York, February 11, 2026, 10:08 EST — Session underway

Concentrix Corp shares dropped 1.8% to $38.55 during Wednesday morning trading, after peaking at $39.52 earlier in the session. The Nasdaq-listed outsourcing firm has seen its stock fluctuate between $38.50 and $39.52, with roughly 32,000 shares traded so far.

The decline occurred despite Wall Street starting off higher, buoyed by a stronger-than-anticipated January jobs report that lifted the S&P 500 and Nasdaq right at the open.

For Concentrix, the key issue is timing. MarketBeat data puts the next earnings release estimated for March 25, following the market close, according to their historical reporting patterns.

The broader tape showed strength. The SPDR S&P 500 ETF climbed roughly 0.5%, while the Invesco QQQ, which tracks the Nasdaq 100, edged up about 0.7% in early trading.

Among the peers, TTEC Holdings slipped roughly 1%, whereas Genpact saw a slight uptick.

A minor shareholder update slipped through this week. Concentrix’s dividend history page shows a $0.36 per share dividend, set to pay on Feb. 10, following a Jan. 30 record date.

The last major update came in January when Concentrix reported its Q4 results, revealing a $1.52 billion goodwill impairment that triggered a sharp operating loss. Despite that, the company posted a non-GAAP EPS of $2.95. CEO Chris Caldwell commented, “The investments we are making in the business are paying off with growth in our intelligent transformation solutions.” The company projected full-year revenue between $10.035 billion and $10.180 billion, with adjusted free cash flow expected to land between $630 million and $650 million. Concentrix Investor Relations

Goodwill represents an accounting asset linked to previous acquisitions. An impairment means writing down that value; usually, it’s a non-cash charge, yet it can draw investor attention to how a stock’s valuation is reflected in reported earnings.

“Non-GAAP” results exclude specific items—typically large charges like impairments—to provide a clearer picture of core operations. Free cash flow represents the cash remaining after capital expenditures, available for debt repayment, buybacks, or dividends.

The downside remains clear: if client demand weakens or costs rise, the margin and cash-flow narrative falters, making it tough for the stock to keep up on market upswings.

Next on the earnings calendar: Public.com shows the next report expected on March 25, 2026. Analysts are forecasting EPS of $2.52, making this a key date for traders tracking growth and cash flow updates.

Marcin Frąckiewicz

Marcin Frąckiewicz is the CEO of TS2 Space and a longtime technology entrepreneur focused on telecommunications, satellite communications and digital innovation. A graduate of the Warsaw School of Economics (SGH), he writes about space technology, artificial intelligence and publicly traded technology companies. His analysis covers major market trends, emerging technologies and the businesses shaping the future of the global economy.

Stock Market Today

  • FTSE 100 Drops 0.61% as AstraZeneca Hit by Drug Trial Miss
    July 9, 2026, 9:41 AM EDT. The FTSE 100 fell 0.61% to 10,424.59 after AstraZeneca shares sank. Its heart drug Wainua missed the primary endpoint in a key trial, wiping as much as £23.3 billion from AstraZeneca's value. The news threw a wrench in AstraZeneca's $80 billion revenue target for 2030, according to BofA's Sachin Jain. The FTSE 250 managed a 0.28% gain, boosted by Computacenter after the company said first-half profit could double thanks to strong demand and AI contracts. Playtech was also among the top mid-cap movers. Trading stayed volatile with Middle East worries and moving oil prices. In the U.S., Ionis fell in premarket, while rivals Alnylam and BridgeBio jumped 11-16% on their approved treatments for the same heart condition.